MedTrace Logo

Intravitreal Ranibizumab in Recurrent ROP

NCT04539106 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2020-09-04

No results posted yet for this study

Summary

A retrospective study included reviewing of medical records of preterm babies who were admitted in neonatal intensive care unit (NICU) of Mansoura University children hospital (MUCH) or referred from nearby hospitals for ROP screening during the period from March 2013 to February 2020.

Conditions

  • Retinopathy of Prematurity

Interventions

DRUG

intravitreal injection of Ranibizumab

intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus

Sponsors & Collaborators

  • Ameera Gamal Abdelhameed

    lead OTHER

Principal Investigators

  • Rania MR Bassiouny, MD · Mansoura University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-02-01
Completion
2020-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539106 on ClinicalTrials.gov